Coya Therapeutics, Inc. (COYA) Current Ratio
- Current ratio · latest quarter: Value 13.40×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 13.40× | Current assets / current liabilities. $47.06M ÷ $3.51M ≈ 13.40× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 47.06M USD | Assets, Current |
| Current obligations | 3.51M USD | Liabilities, Current |
| Cash and equivalents | 43.18M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.09M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $47.06M | $3.51M | $43.18M | (m) | (m) | (m) | $1.09M | (m) | 13.40× |
| 2026-03-31 | $53.26M | $3.55M | $50.72M | (m) | (m) | (m) | $948.19K | (m) | 15.02× |
| 2025-12-31 | $49.94M | $5.87M | $46.82M | (m) | (m) | (m) | $1.06M | (m) | 8.50× |
| 2025-09-30 | $32.02M | $3.67M | $28.13M | (m) | (m) | (m) | $1.11M | (m) | 8.73× |
| 2025-06-30 | $33.43M | $4.50M | $29.76M | (m) | (m) | (m) | $931.34K | (m) | 7.43× |
| 2025-03-31 | $38.37M | $4.34M | $35.53M | (m) | (m) | (m) | $1.69M | (m) | 8.84× |
| 2024-12-31 | $44.31M | $3.82M | $38.34M | (m) | (m) | (m) | $1.59M | (m) | 11.59× |
| 2024-09-30 | $35.51M | $2.32M | $31.06M | (m) | (m) | (m) | $336.72K | (m) | 15.31× |
| 2024-06-30 | $39.89M | $3.83M | $36.58M | (m) | (m) | (m) | $1.88M | (m) | 10.43× |
| 2024-03-31 | $37.33M | $4.32M | $35.99M | (m) | (m) | (m) | $1.59M | (m) | 8.64× |
| 2023-12-31 | $41.20M | $5.05M | $32.63M | (m) | (m) | (m) | $1.16M | (m) | 8.15× |
| 2023-09-30 | $11.82M | $1.81M | $10.89M | (m) | (m) | (m) | $633.95K | (m) | 6.54× |
| 2023-06-30 | $14.39M | $1.22M | $13.10M | (m) | (m) | (m) | $237.58K | (m) | 11.78× |
| 2023-03-31 | $17.33M | $1.27M | $16.32M | (m) | (m) | (m) | $541.75K | (m) | 13.69× |
| 2022-12-31 | $7.18M | $3.82M | $5.93M | (m) | (m) | (m) | $1.82M | (m) | 1.88× |
| 2021-12-31 | $4.58M | $1.15M | $4.34M | (m) | (m) | (m) | $857.57K | (m) | 3.99× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |